https://www.selleckchem.com/pe....ptide/tirzepatide-ly
MSCs can overcome the clinical challenges currently faced by SARS-CoV-2 infected patients, specifically who are seriously ill and not responding to conventional therapies. Though the available clinical data is motivating, still predicting the therapeutic potential of MSCs will be too early in COVID-19. Hence, further studies in a larger cohort of patients becomes a prerequisite to validate their potential efficacy. MSCs can overcome the clinical challenges currently faced by SARS-CoV-2 infected patients, specifically who ar
Curtir
Comentario
Compartilhar
